BioMarin Pharma (BMRN) Tops Q4 EPS by 17c, Offers FY Guidance
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.08, $0.17 better than the analyst estimate of ($0.09). Revenue for the quarter came in at $454.4 million versus the consensus estimate of $459.33 million.
GUIDANCE:
BioMarin Pharma sees FY2020 revenue of $1.95-2.05 billion, versus the consensus of $1.95 billion.
Item | 2020 Guidance | ||||||||
Total Revenues | $1,950 | to | $2,050 | ||||||
Vimizim Net Product Revenues | $560 | to | $610 | ||||||
Kuvan Net Product Revenues | $430 | to | $480 | ||||||
Naglazyme Net Product Revenues | $380 | to | $420 | ||||||
Palynziq Net Product Revenues | $180 | to | $210 | ||||||
Brineura Net Product Revenues | $85 | to | $115 | ||||||
Cost of Sales (% of Total Revenues) | 20 | % | to | 21 | % | ||||
Research and Development Expense | $675 | to | $725 | ||||||
Selling, General and Administrative Expense | $780 | to | $830 | ||||||
GAAP Net Income (1) | $20 | to | $80 | ||||||
Non-GAAP Income (2) | $260 | to | $310 | ||||||
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.